Skip to main content

Precision Biosciences(Nasdaq: DTIL) Portfolio, Stock and Financial Highlights

Precision BioSciences, Inc. Highlights

- Clinical-stage biotechnology company dedicated to improving life 
- Utilizes novel and proprietary ARCUS® genome editing platform
- Developing Off-shelf Allogeneic CAR T cells & In vivo editing tools 
- Net loss was $26.0 million
- Approximately $104.1 million in cash and cash equivalents.

Precision BioSciences, Inc. is a clinical-stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist.

Stock Information: (Nasdaq: DTIL) 
AAPL Chart by TradingView


Precision Biosciences Therapeutic Area & Portfolio



Off the Shelf Allogeneic CAR T Portfolio
PBCAR0191: In August 2020, Precision announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to PBCAR0191 for B-ALL. Precision also holds Orphan Drug Designation from the FDA for this program in mantle cell lymphoma (MCL), an aggressive subtype of non-Hodgkin lymphoma (NHL). PBCAR0191 is being developed in collaboration with Servier. Precision expects to present updated interim clinical data from both the NHL and B-ALL cohorts of this trial before year-end 2020 via a Company-sponsored event.

PBCAR269A
 PBCAR269A (wholly owned) is an investigational allogeneic CAR T candidate targeting B-cell maturation antigen (BCMA), for the treatment of R/R multiple myeloma. PBCAR269A has received granted orphan drug destination and fast track designations.

PBCAR020A
 Precision continues to enroll patients in the PBCAR020A, a wholly-owned investigational allogeneic anti-CD20 CAR T therapy, in patients with R/R NHL including patients with R/R chronic lymphocytic leukemia or R/R small lymphocytic lymphoma. 

In Vivo Gene Correction Portfolio:

PH1 Program:
Pre-clinical research has continued to progress for Precision’s wholly-owned primary hyperoxaluria type 1 (PH1) gene correction program, which is designed to use ARCUS to knock-out the HAO1 gene as a potential one-time treatment for this rare genetic disease. The Company expects to provide an update on this program in the first half of 2021.

Collaborations
In September 2020, Precision announced a clinical collaboration with SpringWorks Therapeutics to evaluate PBCAR269A in combination with nirogacestat, SpringWorks’ investigational gamma secretase inhibitor. The companies have formed a joint steering committee to oversee the combination arm of Precision’s Phase 1/2a clinical study, which is expected to commence in the first half of 2021, pending discussions with regulators.

In November 2020, Eli Lilly and Company (NYSE: LLY) and Precision BioSciences, Inc. (Nasdaq: DTIL) announced a research collaboration and exclusive license agreement to utilize Precision's proprietary ARCUS® genome editing platform for the research and development of potential in vivo therapies for genetic disorders, with an initial focus on Duchenne muscular dystrophy (DMD) and two other undisclosed gene targets.

Financial Highlights for Q3 2020

Cash and Cash Equivalents: As of September 30, 2020, Precision had approximately $104.1 million in cash and cash equivalents.

Revenues: Total revenues for the quarter ended September 30, 2020 were $7.4 million

Research and Development Expenses: Research and development expenses were $24.9 million for the quarter ended September 30, 2020.

General and Administrative Expenses: General and administrative expenses were $8.5 million for the quarter ended September 30, 2020

Net Loss: Net loss was $26.0 million, or $(0.50) per share, for the quarter ended September 30, 2020, compared to a net loss of $20.7 million, or $(0.41) per share, for the same period in 2019.

Reference 
www.precisionbiosciences.com
https://precisionbiosciences.com/wp-content/uploads/2020/11/Precision-BioSciences-Corporate-Deck-November-2020-vF_.pdf
Labels:

Comments

Post a Comment

Popular posts from this blog

MCQs on Neisseria gonorrhoeae and Neisseria meningitidis: Medical microbiology

                                                       Multiple Choice Questions on Neisseria species (Gram-negative cocci) 1) A 19-year-old female college freshman, presented to the university health center with a severe headache, fever, and a stiff neck. She lived in a dormitory and was active in various social activities. She had received all her childhood vaccinations but had not received a booster for the meningococcal vaccine recommended before college entry. Clinical Presentation: On day 1, the patient experienced a sudden onset of fever (39.5°C or 103.1°F), severe headache, nausea, and vomiting. She also noticed a rash on her trunk and legs. Over the next two days, her symptoms deteriorated further, leading to photophobia and altered mental status. Concerned, her roommates brought her to the university health center. Physical Examinati...
4 comments
Read More

Multiple Choice Questions (MCQs) on Diabetes Mellitus: Pathogenesis, Diagnosis and Treatment

                                        MCQs on Diabetes mellitus 1) Diabetes mellitus is a disorder characterized by hyperglycemia.  Which of the following is not the common characteristic features of type 2 diabetes mellitus ? a) Impaired insulin secretion b) Increased Insulin resistance  c) Diabetic ketoacidosis d) Excessive hepatic glucose production 2) Which of the following are the characteristic features of type 1 diabetes mellitus? a) Type 1 diabetes is caused by an absolute deficiency of insulin. b) Type 1 diabetes is associated with the autoimmune destruction of beta cells.  c) Patients with  uncontrolled type 1 diabetes present with diabetic ketoacidosis d) All of the above   3) Which of the following serum measurements are not used for the diagnosis of diabetes mellitus? a) Fasting blood glucose d) Postprandial blood glucose  c) Insulin ...
6 comments
Read More

Pentose Phosphate Pathway: Source of NADPH for Reductive Biosynthesis (Biochemistry)

Introduction to Pentose Phosphate Pathway The pentose phosphate pathway ( Hexose monophosphate pathway ) is the metabolic pathway that occurs in the cytosol and generates NADPH (nicotinamide adenine dinucleotide phosphate) which is utilized in various biosynthetic pathways. This pathway can be broadly classified into two phases i.e oxidative phase and non-oxidative phase.  In the oxidative stage of the pentose phosphate pathway, the glucose-6-phosphate is converted to five carbon ribulose-5 phosphate with generation of NADPH.  During the non-oxidative stage, the interconversion of pentose sugars and hexose sugars is catalyzed by isomerases and aldolases. The fate of these reversible steps depends on the anabolic and energy status of the cells.  The two primary functions of the pentose phosphate pathway are ; a) Provide NADPH (a coenzyme) for biosynthetic pathways b) Provide pentose sugars for nucleotides (DNA and RNA) synthesis Two phases of Pentose phosphat...
2 comments
Read More